A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading
Patients with untreated chronic lymphocytic leukemia experienced prolonged survival when treated with Fludara® (fludarabine) plus Rituxan® (rituximab) (delivered either concurrently or sequentially),... Continue Reading
The U.S. Food and Drug Administration (FDA) has expanded the approval of Rituxan® (rituximab) to include the treatment of certain patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia... Continue Reading
The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory... Continue Reading
According to the results of a study published in the New England Journal of Medicine, chronic lymphocytic leukemia (CLL) appears to be preceded by a condition known as monoclonal B-cell lymphocytosis (MBL). Chronic... Continue Reading